rAAV2-ND4

PreclinicalGene therapy

rAAV2-ND4 is one of 48 small molecule programs targeting Leber hereditary optic neuropathy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Leber Hereditary Optic NeuropathyActive, not recruiting

NeuropathyActive, not recruiting

Leber Hereditary Optic NeuropathyPreclinical

Active, not recruiting

NeuropathyPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

114 competitors in Neuropathy

#DrugCompanyPhaseTrials

Asceniv

CSL Behring

Phase 3

1 2

Avandia

Alnylam Pharmaceuticals

Phase 3

1 3

Vimpat

UCB

Phase 3

1 4

Savella

AbbVie

Phase 3

1 5

Avicel

SSanthera Pharmaceuticals

Phase 3

3 6

Claritin

PPerrigo Company

Phase 3

1 7

Prilosec

DDexcel Pharma Technologies Ltd.

Phase 3

1 8

Glutamine

Sanofi

Phase 3

2 9

Curcumin

Merck & Co.

Phase 3

1 10

Taxol

Teva

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Leber hereditary optic neuropathy1 trial

Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy (LHON)

Completed·BBin Li·N/A·NCT01267422·9 enrolled

Neuropathy1 trial

A Single Intravitreal Injection of rAAV2-ND4 for the Treatment of Leber's Hereditary Optic Neuropathy

Unknown status·HHuazhong University of Science and Technology·Phase 2/3·NCT03153293·159 enrolled

Gene Therapy1 trial

Efficacy Study of Gene Therapy for The Treatment of Acute LHON Onset Within Three Months

Unknown status·BBin Li·N/A·NCT03428178·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for rAAV2-ND4. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — rAAV2-ND4 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for rAAV2-ND4. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bin Li company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Gene therapy[2]
Highest Phase: Preclinical[1]
Company: BBin Li

rAAV2-ND4

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Leber hereditary optic neuropathy1 trial

Neuropathy1 trial

Gene Therapy1 trial

References

Drug Info

Quick Facts

Related News